Home Pitango partner talks new $175M health tech fund, AI, and ro... Last week, Israel’s Pitango VC announced the closing of its second healthcare-focused fund, Pitango HealthTech II.
News Novo Nordisk obesity drug linked to rare cause of sight loss The EMA has become the first regulator to link the use of Novo Nordisk's GLP-1 agonist semaglutide with sight-robbing disorder NAION.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
